Postoperative (chemo) radiation in patients with squamous cell cancers of the head and neck - clinical results from the cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer" by Maihoefer, Cornelius et al.
RESEARCH Open Access
Postoperative (chemo) radiation in patients
with squamous cell cancers of the head
and neck – clinical results from the cohort
of the clinical cooperation group
“Personalized Radiotherapy in Head and
Neck Cancer”
Cornelius Maihoefer1,2* , Lars Schüttrumpf1,2, Corinna Macht3, Ulrike Pflugradt1,2, Julia Hess1,4,
Ludmila Schneider1,4, Christine Woischke1,6, Axel Walch7, Philipp Baumeister1,5, Thomas Kirchner1,6,
Horst Zitzelsberger1,4, Claus Belka1,2 and Ute Ganswindt1,2,8
Abstract
Background: Postoperative (chemo) radiation improves tumor control and survival in high-risk patients with head
and neck squamous cell carcinoma based on established risk factors. The clinical cooperation group “Personalized
Radiotherapy in Head and Neck Cancer” focuses on the identification and validation of new biomarkers, which are
aimed at eventually stratifying and personalizing the therapy concept. Hence, we reviewed all patients with head
and neck squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx, treated with
postoperative (chemo) radiation from 06/2008 until 06/2015 at the Department of Radiation Oncology in the
University Hospital, LMU Munich. Here we report the clinical results of the cohort, laying the foundation for further
research within the framework of a clinical cooperation group.
Methods: Patient data were retrospectively (until 2013) and prospectively (from 2013) collected and analyzed for
outcome and treatment failures with regard to previously described and established risk factors.
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Results: We identified 302 patients (median follow-up 45 months, average age 60.7 years), having received
postoperative (chemo)radiation (median 64 Gy). Chemotherapy was added in 58% of cases, mostly Cisplatin/5-
Fluorouracil in concordance with the ARO 96–3 study. The 3-year overall survival, local, locoregional and distant
failure estimates were 70.5, 9.7, 12.2 and 13.5%, respectively. Human papillomavirus-associated oropharyngeal
cancer was associated with a significant improved overall survival, locoregional, distant and overall tumor control
rates in multivariate analysis. Additionally, in multivariate analysis, for local failure, resection status and perineural
invasion, for locoregional and distant failure extracapsular extension and for overall survival the presence of nodal
disease were significant adverse factors. Moreover, 138 patients have been treated in concordance with the ARO
96–3 protocol, corroborating the results of this study.
Conclusions: Our cohort represents a large unselected cohort of patients with head and neck squamous cell
carcinoma treated with postoperative (chemo)radiation. Tumor control rates and survival rates are consistent with
the results of previously reported data.
Keywords: Head and neck cancer, Squamous cell carcinoma, Postoperative, Adjuvant, Chemoradiation, Radiation
therapy, Radiotherapy, HPV, HNSCC,
Background
Postoperative (chemo)radiation is the standard treat-
ment for patients with head and neck squamous cell car-
cinoma (HNSCC) presenting with established risk
factors such as large primary tumors, positive nodal in-
volvement, and close or incomplete resection margins
after surgery [1–7]. Since the joint analysis by Cooper
and Bernier, close or incomplete resection margins or
lymph nodes with extracapsular spread are established
risk factors for the indication of additional chemother-
apy [8, 9]. However, the prognosis of patients with
HNSCC is still to be improved [10, 11]. At the same
time, Human papillomavirus (HPV)-associated oropha-
ryngeal carcinoma (HPVOPC) have a much better out-
come than HPV-negative HNSCC [12–15].
Due to rigid inclusion and exclusion criteria, most
studies do not represent the usual “everyday” patient.
Here we describe an unselected cohort of patients that
have been treated with postoperative (chemo)radiation
in our department. This cohort (LMU-KKG) lays the
foundation for ongoing and future research such as the
establishment of new biomarkers and the personalization
of head and neck oncology in the context of the multi-
disciplinary translational Clinical Cooperation Group
(CCG; german: KKG) “Personalized Radiotherapy in
Head and Neck Cancer”.
Methods
We analyzed 302 patients with squamous cell carcinoma
of the oral cavity, oropharynx, hypopharynx and larynx
who have been treated with postoperative radiation ther-
apy in our clinic (Department of Radiation Oncology,
University Hospital, LMU Munich) between 06/2008
and 06/2015 retrospectively (until 2013) and prospect-
ively (from 2013). From 2013 onwards, the data acquisi-
tion was conducted prospectively within the framework
of the clinical cooperation group “Personalized Radio-
therapy in Head and Neck Cancer”. Patients aged at
least 18 years with the aforementioned tumor sites and
histology were included. Basically, all patients with
HNSCC were permitted in the prospective collection co-
hort, but only those with surgery followed by adjuvant
(chemo)radiation were included in this analysis.
Patients with risk factors such as large primary tumors
(pT3/pT4), positive nodal involvement (≥pN1), close (<
5 mm), incomplete resection margins or in some cases
previously not irradiated recurrent tumors were treated
with postoperative radiation therapy. The advised dose
was usually 64–66 Gy to the former tumor bed, 50–
54 Gy to the elective nodal levels and 56–60 Gy to in-
volved nodal levels; both 3D- and IMRT-technique
(intensity-modulated radiotherapy) have been used. In
cases of close or incomplete resection margins or lymph
nodes with extracapsular extension (ECE) patients
underwent additional chemotherapy, consisting of Cis-
platin/5-Fluorouracil (CDDP/5-FU) in concordance with
the ARO 96–3 Study (CDDP (20 mg/m2 on day 1–5,
29–33) and 5-FU (600 mg/m2 on day 1–5, 29–33) [9].
The reasons for selecting this regimen were positive
treatment experiences during the participation in the
study and the promising results presented at the
ASCO-Meeting in 2009. However, in 2016 this regimen
was discontinued in favor of CDDP mono, as no pub-
lished solid long-term data further supported the
CDDP/5-FU approach. Other chemotherapeutic regi-
mens (such as CDDP 40 mg/m2 weekly, Mitomycin C
(MMC) 10 mg/m2 d1,d29; 5-FU 600 mg/m2 d1–5,
MMC 10 mg/m2 d5,d36 or Cetuximab 250 mg/m2
weekly with 400 mg/m2 loading dose) were used if a pa-
tient with clear indication for chemoradiation was not
suitable for combined CCDP and 5-FU-based chemo-
therapy due to relevant comorbidities or advanced age
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(e.g. in case of decreased renal function 5-FU/MMC, in
case of cardiac comorbidities CDDP only or in case of
advanced age and reduced performance status switch to
MMC or Cetuximab mono).
The clinic’s radiation therapy management system
(Mosaiq® - Elekta, Sweden) and patient files recorded in
a dedicated Microsoft® Access® Relational Database were
used to collect patient data.
Tumor stage was assessed using the UICC 7th edition
classification, for HPVOPC also UICC 8th edition stages
were added. Resection margins were considered “close
margin” when declared R0, but less than 5 mm by the
local pathologist. Other risk factors were recurrent dis-
ease, lymphovascular invasion (LVI), venous tumor inva-
sion (VTI), perineural invasion (PNI), extracapsular
extension (ECE) and number of involved lymph nodes.
Immunohistochemical (IHC) p16INK4a staining results
from our local pathology was used as a surrogate marker
for HPV-infection, if available (162 patients). Addition-
ally, 124 of the remaining HNSCC patients were ana-
lyzed for HPV p16 within the framework of the KKG.
IHC p16INK4a staining was performed using the CINtec
TM Histology Kit (Roche mtm laboratories AG, Heidel-
berg, Germany) on a Ventana Benchmark LT automated
immunostainer (Ventana Medical Systems, Tucson AZ,
USA) according to the protocol. Tumor specimens with
strong and diffuse nuclear and cytoplasmic staining in
more than 70% of tumor cells were considered as
p16-positive.
Follow-up data has been gathered in the joint sur-
vivorship clinic of the Otorhinolaryngological and the
Radiation Oncology Department of the LMU, but also
from follow-up visits in our clinic, medical records from
external care givers or by telephone (for assessing the
survival only).
Follow-up has been calculated from the first day of ra-
diation therapy with the reverse Kaplan-Meier estimate
[16]. All other endpoints such as survival or time to re-
currence have been calculated from the first day of the
radiation treatment. The events of the survival endpoints
were defined as following: overall survival (OS) – death,
disease-free survival (DFS) – death or any recurrence,
disease-specific survival (DSS) – only death related to
recurring HNSCC. P-values were determined using
log-rank testing for comparison between groups. Univar-
iate and multivariate analyses were conducted using Cox
proportional hazard regression models. If more than one
factor was significant in univariate Cox regression ana-
lysis, multivariate Cox regression analysis with backward
elimination (likelihood ratio) was used for determining
the influence of multiple covariates. If possible by the
number of events, factors with p < 0.1 were also included
in multivariate analysis. Statistical analyses were per-
formed with SPSS V24 (IBM, Chicago, IL) and R
(Version 3.3.1). P-values of < 0.05 were considered statis-
tically significant. Median estimates and Hazard ratios
(HR) with 95% confidence intervals (CI) were deter-
mined. Ethics approval for data gathering and the assess-
ment of tumor probes were granted by the local ethics
committee (No. 448–13, 459–13, 17–116).
Results
Patient and treatment characteristics
A total of 302 patients with HNSCC of the oral cavity,
oropharynx, hypopharynx and larynx were treated with
adjuvant (chemo)radiation therapy in our department
between 06/2008 and 06/2015. Patient, tumor and treat-
ment characteristics are shown in Table 1. The patients’
average age was 60.7 (range 20–87 yr., IQR 54–68 yr) at
time of diagnosis. The median follow-up estimate was
45.0 months (95% CI 41.2–48.8 months, reverse
Kaplan-Meier). 97% of patients completed radiation
therapy and received at least 60 Gy to the tumor bed.
58% of patients (n = 176) received concurrent systemic
therapy.
Tumor control rates and survival data for all patients
For all patients 3 (5) year overall survival estimates were
70.5% (60.2%). The estimated disease-specific and
disease-free survival rates were 85.7 and 64.7% after
3 years, respectively (Fig. 1a). The estimated 3-year fail-
ure rates were 9.7% for local, 12.2% for locoregional,
13.5% for distant and 20.8% for overall failures (Fig. 1b).
Tumor control rates and survival data for patients treated
for recurrent tumors
Patients with tumor recurrence after surgery have also
been treated in the reported timeframe (n = 24; see
Table 1). For patients treated due to recurrent disease
3(5)-year overall survival estimates were 74.6% (65.3%)
in comparison to those not treated for recurrence with
69.6% (59.7%) (not significant; n.s.). The estimated
3-year disease-specific (disease-free) survival rates were
85.3% (67.4%) for the patients treated for recurrence and
85.0% (64.5%) for the patients treated for the first mani-
festation of the tumor (n.s.). The estimated 3-year failure
rates were 15.8% for locoregional, 7.7% for distant and
22.8% for overall failures in the recurrent cohort and
11.9, 14.0 and 20.3% in the non-recurrent cohort (n.s.).
Tumor control rates and survival data for the ARO 96–3
subgroup
One hundred thirty-eight patients were treated with
CDDP/5-FU in concordance to the chemotherapy arm
of the ARO 96–3 study, the patient’s characteristics are
described in Table 1. The estimated median follow-up
was 45 months (95% CI 40.5–49.5 month). 87% of pa-
tients received 2 cycles of chemotherapy; the remaining
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Table 1 Patient and treatment characteristics for all patients (left panel) recurrent patients (middle-left panel) and the ARO-analogue
subgroup (middle-right panel) and patients with HPV-p16 positive oropharyngeal carcinoma (right panel)
Factors All patients
n = 302
Recurrent
n = 24
ARO-analogue
n = 138
HPVOPC
n = 60
Number Percent Number Percent Number Percent Number Percent
Primary Tumor
Oropharynx 149 49.3 4 16.7 76 55.1 60 100.0
Oral cavity 63 20.9 6 25.0 20 14.5 0 0.0
Hypopharynx 39 12.9 3 12.5 24 17.4 0 0.0
Larynx 51 16.9 11 45.8 18 13.0 0 0.0
Sex
male 226 74.8 18 75.0 108 78.3 40 66.7
female 76 25.2 6 25.0 30 21.7 20 33.3
Age
< 45 11 3.6 0 0 5 3.6 5 8.3
45–54 66 21.9 5 20.8 36 26.1 6 10.0
55–64 114 37.7 7 29.2 63 45.7 24 40.0
65–74 88 29.1 9 37.5 32 23.2 19 31.7
> 75 23 7.6 3 12.5 2 1.4 6 10.0
UICC Stage 7th edition (a 8th edition for HPVOPC)
I 7 2.3 4 16.7 0 0.0 1 (42a) 1.7 (70.0a)
II 30 9.9 0 0 5 3.6 4 (16a) 6.7 (26.7a)
III 78 25.8 7 29.2 23 16.7 11 (2a) 18.3 (3.3a)
IV 187 61.9 13 54.2 110 79.7 44 (0a) 73.3 (0.0a)
Diagnosis class
First diagnosis 272 90.1 0 0 125 90.6 59 98.3
Recurrence 24 7.9 24 100.0 11 8.0 1 1.7
Second primary 6 2.0 0 0 2 1.4 0 0
T-Stage
T0 2 0.7 2 8.3 2 1.4 0 0.0
T1 56 18.5 6 25.0 28 20.3 12 20.0
T2 121 40.1 1 4.2 44 31.9 36 60.0
T3 74 24.5 6 25.0 40 29.0 10 16.7
T4 49 16.2 9 37.5 24 17.4 2 3.3
N-Stage
N0 89 29.5 12 50.0 19 13.8 8 13.3
N1 58 19.2 6 25.0 23 16.7 9 15
N2a 23 7.6 0 0 15 10.9 10 16.7
N2b 85 28.1 5 20.8 47 34.1 25 41.7
N2c 42 13.9 1 4.2 30 21.7 8 13.3
N3 5 1.7 0 0 4 2.9 0 0
M-Stage
M0 302 100 24 100 138 100 60 100
M1 0 0 0 0 0 0 0 0
Resection status (R-Status)
R0 150 51.0 7 33.3 47 35.1 26 44.1
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Table 1 Patient and treatment characteristics for all patients (left panel) recurrent patients (middle-left panel) and the ARO-analogue
subgroup (middle-right panel) and patients with HPV-p16 positive oropharyngeal carcinoma (right panel) (Continued)
Factors All patients
n = 302
Recurrent
n = 24
ARO-analogue
n = 138
HPVOPC
n = 60
Number Percent Number Percent Number Percent Number Percent
R0-Close margin 75 25.5 7 33.3 43 32.1 12 20.3
R1 69 23.5 7 33.3 44 32.8 21 35.6
N/A 8 3 4 1
Extracapsular extension (ECE)
no (N0) 89 29.8 12 52.5 19 13.9 8 13.3
no (N+) 132 44.1 6 26.1 59 43.1 34 56.7
yes 78 26.1 5 21.7 59 43.1 18 30.0
N/A 3 1 1 0
Perineural invasion (PNI)
no (Pn0) 198 83.5 8 88.9 86 82.7 41 87.2
yes (Pn1) 39 16.5 1 11.1 18 17.3 6 12.8
N/A 65 15 34 13
Lymphatic Invasion (LI)
no (L0) 201 73.4 11 78.6 82 66.1 40 69.0
yes (L1) 73 26.6 3 21.4 42 33.9 18 31.0
N/A 28 10 14 2
Vascular Invasion (VI)
no (V0) 266 97.1 12 100 119 96.0 55 96.5
yes (V1) 8 2.9 0 0 5 4.0 2 3.5
N/A 28 12 14 3
Grading
G1 9 3.0 2 8.7 2 1.5 0 0.0
G2 119 39.5 11 47.8 45 32.8 11 18.3
G3 173 57.5 10 43.4 90 65.7 49 81.7
N/A 1 1 1 0
HPV p16
negative 159 68.2 11 73.3 66 61.7 0 0.0
positive 74 31.8 4 26.7 41 38.8 60 100.0
HPVOPC 60 20.5 1 6.7 36 25.2 60 100.0
N/A 69 9 31 0
RT dose in tumor bed
< 60 Gy (not completed) 9 3 2 8.3 4 2.9 2 3.3
60–63.9 Gy 8 2.6 0 0 6 4.3 3 5.0
64 Gy 263 87.1 21 87.5 120 87 52 86.7
66 Gy 22 7.3 1 4.2 8 4.8 3 5.0
RT technique
3d-conformal 245 81.1 21 87.5 116 84.1 41 68.3
IMRT 57 18.9 3 12.5 22 15.9 19 31.7
Concomitant chemotherapy
no Chx 126 41.7 10 41.7 0 0.0 16 26.7
despite indicated 43 14.2 5 20.8 0 0.0 4 6.7
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patients did not receive both cycles due to various
reasons (refusal, worsening condition). The estimated
5-year OS, DFS and DSS were 60.6, 56.8 and 76.8%,
respectively (Fig. 1c). The estimated 3-year local,
locoregional and distant failure rates were 7.8, 10.9
and 18.9%, respectively (Fig. 1d). HPV-p16-status
was associated with a significantly improved locore-
gional control, distant control, DFS, DSS and OS in
the ARO-analogue group (data not shown).
Risk factors
Previously described risk factors, such as large pri-
mary tumors (pT3 or pT4) the presence of positive
lymph nodes with and without extranodal disease
(ECE), positive resection margins (R1), lymphangiosis
(LVI), perineural invasion (PNI) and positive prog-
nostic factors such as HPV-p16-positive oropharyn-
geal carcinoma (HPVOPC) were analyzed for
correlation with local control, locoregional control,
distant control, any control, overall survival (OS),
disease-specific survival (DSS) and disease-free sur-
vival (DFS) in univariate and multivariate cox regres-
sion analysis (see Table 2, Fig. 2a-d).
HPV- p16 positive oropharyngeal carcinoma
Patients with HPV-p16 positive oropharyngeal carcin-
oma (HPVOPC) have been analyzed separately (n = 60,
estimated median follow-up 45 months). With only one
local, one regional and three distant recurrences in 4 pa-
tients, the 3-year local, locoregional, distant and overall
failure estimates (1.8, 4.2, 4.6 and 6.2%) were signifi-
cantly lower in patients with HPVOPC compared to all
other non HPVOPC (13.3, 15.9, 16.8 and 26.5%)
(Fig. 3a-d). The 3-year OS, DSS and DFS rates of
HPVOPC were significantly better with 88.6, 97.5 and
85.1% compared to 63.7, 81.6 and 56.4% of all other non
HPVOPC. Also, when comparing only within the sub-
group of OPC (n = 65), OS, DFS, DSS and the overall re-
currence rate, were significantly better in HPVpos OPC
then in HPV neg OPC (3-year estimates: 60.2, 58.5, 83.4
and 20.8%) (Fig. 3e+f ).
Discussion
The present study represents a well-established and
thoroughly followed up cohort of 302 “everyday pa-
tients”, treated for tumors of the oral cavity, oropharynx,
hypopharynx and larynx with postoperative (chemo) ra-
diation in our clinic between 06/2008 and 08/2015.
Table 1 Patient and treatment characteristics for all patients (left panel) recurrent patients (middle-left panel) and the ARO-analogue
subgroup (middle-right panel) and patients with HPV-p16 positive oropharyngeal carcinoma (right panel) (Continued)
Factors All patients
n = 302
Recurrent
n = 24
ARO-analogue
n = 138
HPVOPC
n = 60
Number Percent Number Percent Number Percent Number Percent
Med. 20 4 0 0.0 2 3.3
Pat. Refusal 23 1 0 0.0 2 3.3
Any Chemo 176 58.3 14 58.3 138 100.0 44 73.3
CDDP/5-FU 138 78.4 11 45.8 138 100.0 36 81.8
CDDP mono 9 5.1 1 4.2 0 0.0 3 6.8
Cetuximab 1 0.6 0 0 0 0.0 0 0.0
5-FU/MMC 8 4.5 1 4.2 0 0.0 3 6.8
MMC 20 11.4 1 4.2 0 0.0 2 4.5
Chemo completed 147 83.5 14 58.3 120 87.0 36 81.8
Chemo stopped 29 16.5 0 18 13.0 8 18.1
patient refused 8 0 6 2
Worsening condition 7 0 3 3
cytopenia 9 0 4 1
reaction to chemo 5 0 5 2
Death causes
Tumor-related 42 3 21 1
comorbidities 40 3 13 6
therapy-associated 2 0 0 1
Second primary 8 0 4 0
other 5 0 3 0
aThe UICC 8th edition stage is shown in parenthesis (HPVOPC only)
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A clear limitation of our study is the obvious selection
bias by only including irradiated patients and the partly
retrospective nature of the study. Additionally, we report
a heterogeneous cohort with patients partly treated for
recurrence (7.9% or second primaries (2.0%), therefore
the results should be interpreted with some caution.
However, the results of our study are in good agree-
ment with previously published cohorts such as
RTOG-9501 [17], RTOG-0234 [18], EORTC 22931 [2]
and ARO 96–3 [9].
ARO 96–3 is a trial that studied the addition of CDDP
and 5-FU to adjuvant radiation in high-risk patients. In
ARO 96–3 (chemotherapy arm, 226 patients) and
LMU-ARO (ARO-analogue subgroup, 138 patients)
5-year locoregional failure rates were 11.4 and 10.9%,
the 5-year distant failure rates were 25.5 and 23% and
the 5-year OS rates were 58.1 and 60.6%, respectively.
The patients’ characteristics of our subgroup repre-
sents a high-risk group with UICC stage III 16.7%, stage
IV 80.7, 32.8% R1, 32.1% close margin and 43.1% ECE,
33.9% LVI. 25.2% of the patients had HPVOPC. Overall,
the ARO 96–3 chemotherapy regimen was well tolerated
which is indicated by the fact that 87% of the patients
completed both cycles chemotherapy as intended. With
138 patients treated, the LMU-ARO subgroup is to our
knowledge the largest published cohort of patients
treated with CDDP/5-FU, supporting its feasibility and
corroborating the preliminary results of the ARO 96–3
study. It should be mentioned, that this regimen was dis-
continued in 2016 due to the lack of solid published
long-term data, adopting CDDP mono as new standard
of care.
Also, the results are in line with other studies with
PORT-C (EORTC 22931, RTOG-9501, RTOG-0234).
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Fig. 1 Kaplan-Meier plots a Overall survival (OS), disease-free survival (DFS) and disease-specific survival (DSS) of all patients b local, locoregional,
distant and any failure rates of all patients. c overall survival (OS), disease-free survival (DFS) and disease-specific survival (DSS) of the ARO-analogue
subgroup d local, locoregional, distant and any failure rates of the ARO-analogue subgroup. Follow-up time was clipped at 60 months. Patients at risk
are displayed under the respective plots. Censors are represented by crosses. P-Values (Log Rank) are shown
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Table 2
Univariate Multivariate
HR 95% CI p-Value HR 95% CI p-Value
Local failure (LF)
HPVOPC 0.128 0.017-0.945 0.044*a 0.146 0.019-1.115 0.064
≥T3 1.580 0.731-3.413 0.244 - - -
ECE vs N+ b 2.849 1.014-8.007 0.047*a 2.262d 0.711-7.199 0.167
N+ vs N0 b 0.350 0.129-0.946 0.039*a 0.555d 0.173-1.779 0.322
pos. Marginsc 2.730 1.016-7.333 0.046*a 3.354 1.206-9.329 0.020*a
LVI 1.660 0.696-3.962 0.253 - - -
PNI 2.853 1.137-7.154 0.025*a 2.590 1.014-6.616 0.047*a
Rec. Tumor 1.730 0.519-5.761 0.372 - - -
Locoreginal failure (LRF)
HPVOPC 0.208 0.050-0.868 0.031*a 0.210 0.049-0.894 0.035*a
≥T3 1.470 0.742-2.912 0.270 - - -
ECE vs N+ 2.855 1.167-6.985 0.022*a 2.939 1.155-7.473 0.024*a
N+ vs N0 0.398 0.165-0.960 0.040*a 0.468 0.167-1.312 0.149
pos. margins 1.610 0.781-3.317 0.197 - - -
LVI 2.063 0.984-4.323 0.055 2.214 0.967-5.067 0.060
PNI 1.844 0.779-4.363 0.164 - - -
Rec. Tumor 1.309 0.399-4.289 0.657 - - -
Distant failure (DF)
HPVOPC 0.267 0.082-0.870 0.028*a 0.153 0.036-0.644 0.010*a
≥T3 1.573 0.838-2.850 0.158 - - -
ECE vs N+ 3.408 1.621-7.164 0.001*a 3.109 1.369-7.035 0.007*a
N+ vs N0 0.812 0.336-1.957 0.642 0.759 0.287-2.004 0.578
pos. margins 0.774 0.411-1.458 0.428 - - -
LVI 1.947 0.995-9.810 0.052 1.963 0.932-4.137 0.076
PNI 1.463 0.634-3.372 0.372 - - -
Rec. Tumor 0.319 0.044-2.324 0.259 - - -
Any failure (AF)
HPVOPC 0.232 0.084-0.643 0.005*a 0.161 0.050-0.523 0.002*a
≥T3 1.629 0.973-2.728 0.064 1.476d 0.822-2.648 0.192
ECE vs N+ 3.126 1.668-5.858 <0.001*a 3.113 1.566-6.187 0.001*a
N+ vs N0 0.604 0.305-1.195 0.148*a 0.669 0.302-1.484 0.323
pos. margins 1.018 0.603-1.719 0.947 - - -
LVI 1.943 1.107-3.412 0.021*a 1.996 1.071-3.720 0.030*a
PNI 1.609 0.820-3.155 0.166 - - -
Rec. Tumor 0.949 0.344-2.622 0.920 - - -
Overall survival (OS)
HPVOPC 0.277 0.134-0.573 0.001*a 0.254 0.116-0.557 0.001*a
≥T3 1.385 0.926-2.072 0.113 - - -
ECE vs N+ 1.684 1.065-2.663 0.027*a 1.393 0.834-2.327 0.205
N+ vs N0 1.127 0.675-1.883 0.647 1.984 1.091-3.610 0.025*a
pos. margins 0.745 0.497-1.116 0.154 - - -
LVI 1.284 0.799-2.064 0.302 - - -
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Comparing the LMU-ARO subgroup to RTOG-9501
(5-year locoregional failure rate 10.9% vs 22%, 3-year OS
71% vs 56%), the RTOG cohort (PORT 60/2 Gy with
CDDP 100 mg/m2 BSA) had younger patients with similar
rates of positive margins, a comparable proportion of oro-
pharyngeal carcinoma (48% vs 55%) but higher rates of at
least two affected lymph nodes and/or ECE (83% vs 67%).
In comparison of LMU-ARO to EORTC 22931 (5-year
locoregional failure rate 10.9% vs 18%, 5-year OS 60.6% vs
53%), the EORTC (PORT 66/2 Gy with CDDP 100 mg/m2
BSA) cohort had also younger patients, comparable rates
of positive margins and positive lymph nodes, but higher
rates of ECE (61% vs 43%), more T4-Tumors (43% vs 17%)
and less oropharyngeal carcinomas (32% vs 55%). The
newer RTOG-0234 study compared CDDP+Cetuximab vs
Docetaxel+Cetuximab with the docetaxel arm performing
better in terms of OS, DFS and distant failure rate. Com-
pared to the RTOG-0234 docetaxel arm (19.9%) and the
CDDP arm (19.8%), with 9.7% less locoregional failures
after two years were observed in the LMU-ARO subgroup.
With a 2-year distant metastasis rate of 16.5%, the
LMU-ARO subgroup ranges between the RTOG-0234
docetaxel (13.2%) and the CDDP-Arm (25.0%). The 2-year
DFS and OS or the LMU-ARO subgroup was comparable
to the Docetaxel-Arm of RTOG 0234 with 69.1% vs 65.9
and 78.1% vs 79.2%, respectively. RTOG 0234 in compari-
son to the LMU-ARO subgroup had younger patients,
more stage IV patients (94% vs 81%), more positive mar-
gins (40% vs 33%), more ECE (60% vs 43%), less oropha-
ryngeal carcinoma (34% vs 55%), but the same rate of
HPVOPC (26% vs 25,2%).
Twenty-four patients in our cohort have been treated
due to recurrence of a previously only surgically treated
HNSCC. Interestingly, the recurrence or survival end-
points did not differ significantly from the entire cohort
in uni- and multivariate analysis. This could be attribut-
able to a selection bias of only re-operating patients with
surgically manageable recurrences (R1-Rate 33.3%), ex-
cluding patients with fulminant recurrences and thus
selecting for less aggressive tumor biology.
In the recent decade, it became evident that HPVOPC
represents a distinct subgroup of patients with a different
prognosis [12, 19]. Also, in our cohort, oropharyngeal car-
cinoma with positive p16 IHC-staining (HPVOPC)
Table 2 (Continued)
Univariate Multivariate
HR 95% CI p-Value HR 95% CI p-Value
PNI 1.666 0.995-2.790 0.052 1.462d 0.853-2.506 0.167
Rec. Tumor 0.816 0.357-1.864 0.630 - - -
Disease specific survival (DSS)
HPVOPC 0.076 0.010-0.557 0.011*a 0.079 0.011-0.576 0.012*a
≥T3 1.839 1.003-3.373 0.049*a 1.719 0.910-3.250 0.095
ECE vs N+ 2.837 1.366-5.892 0.005*a 2.160 1.021-4.571 0.044*a
N+ s N0 0.668 0.300-1.486 0.322 1.093 0.484-2.463 0.831
pos. margins 0.522 0.220-1.239 0.140 - - -
LVI 1.628 0.832-3.187 0.155 - - -
PNI 1.791 0.842-3.812 0.130 - - -
Rec. Tumor 0.965 0.298-3.124 0.953 - - -
Disease free survival (DFS)
HPVOPC 0.300 0.156-0.575 <0.001*a 0.294 0.146-0.590 0.001*a
≥T3 1.463 1.005-2.130 0.047*a 1.369d 0.873-2.146 0.171
ECE vs N+ 2.003 1.305-3.077 0.001*a 1.876 1.159-3.035 0.010*a
N+ vs N0 1.001 0.618-1.621 0.997 1.684 0.949-2.985 0.075
pos. margins 1.191 0.778-1.824 0.420 - - -
LVI 1.512 0.985-2.322 0.059 1.170d 0.718-1.906 0.528
PNI 1.604 0.984-2.613 0.058 1.236d 0.733-2.081 0.427
Rec. Tumor 0.854 0.397-1.836 0.685 - - -
aP-values < 0.05 were marked with asterisk
bNodal positive patients with ECE have been compared against nodal positive patients without ECE (ECE vs N+) and nodal positive patients without ECE against
patients without nodal disease (N+ vs N0) to calculate the excess risk of ECE to nodal disease only
cClose margin vs R0 was neither significant in univariate (HR = 2.200, p = 0.128), nor in multivariate (HR 1.113, p = 0.865) Factors eliminated during the backward-
selection are shown for the sake of completeness in grey letters in multivariate analysis
dFactors eliminated during the backward-selection are shown for the sake of completeness in multivariate analysis
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performed significantly better for locoregional failure, dis-
tant failure, any failure, DSS, DFS and OS (Table 2, Fig. 3).
The 2-year locoregional failure, DFS and OS estimates
were 1.8, 89.8 and 93.3%. Furthermore, in multivariate
analysis, patients with HPVOPC performed significantly
better with regards to all endpoints, except for local failure
(p = 0.064) compared with non HPVOPC. In comparison
to other cohorts that analyzed HPVOPC, the failure and
survival rates are quite similar (DKTK-ROG [14, 20] p16
IHC: 2-year locoregional failure rage 1.6%, 2-year OS
96.9%, RTOG-0234 p16 subgroup: 2-year DFS 76.2%
(Doc), 86.4% (Cis), 2-year OS 100% (Doc), 90.9% (Cis);
Vienna [15]: 2-year OS 91%; Japan 5-yr OS 84.9% [21] vs
LMU 79.9%) With only one local, one regional and three
distant recurrence in the HPVOPC group the need for
studies investigating treatment de-escalation in selected
patients is underlined [22, 23]. Interestingly, re-classifying
the HPVOPC group according to the new UICC 8th edi-
tion, a massive stage migration can be observed. Whereas
in UICC 7th edition 18.3 and 73.3% of the tumors have
been classified as stage III and IV, in UICC 8th edition
only 2 tumors are stage III and no tumors qualify for stage
IV (see Table 1). 70.0 and 26.7% of the HPVOPC are now
classified as stage I or II, reflecting the good prognosis for
this disease [19, 24, 25]. As of now, HPVOPC is still being
treated similar to non HPVOPC due to the lack of clinical
evidence. However, de-escalation strategies are being in-
vestigated in clinical trials: The PATHOS trial [26], the
ECOG trial [27] the DART-HPV-trial [28], the DELPHI
trial [29] and the ADEPT-trial [30] will hopefully provide
new evidence for the feasibility and safety of dose or
chemotherapy modifications for HPVOPC in the adjuvant
setting.
With a high availability of pathological factors, such as
resection status (97.4%) ECE (99.0%), LI (90.7%), VI
(90.7%) and HPV-p16-status (77.2% of all tumors; 84%
of oropharyngeal tumors), a long-time follow-up (me-
dian 45 months) and well documented events (26 local,
33 locoregional, 39 distant recurrences and 97 deaths)
our study provides valid data for extensive statistical
analysis. In uni- and multivariate analysis previously de-
scribed risk factors could be confirmed, although as a
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clear limitation the inclusion of only patients in need for
adjuvant (chemo)radiation harbors an intrinsic selection
bias. In addition, the results of the analysis should be
interpreted with caution due to its retrospective nature.
By focusing on known risk factors in the analyses, the
risk of multiple testing is limited. In multivariate analysis
risk factors such as positive resection margins (HR
3.354, p = 0.020) and PNI (HR 2.590, p = 0.047) were sig-
nificantly associated with higher risk for local recurrence
(Table 2). Close margins were not significantly
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associated with higher risk for local recurrence (multi-
variate HR = 1.113, p = 0.865), however, in our clinic
most patients with close margins had concomitant
chemotherapy, thus a concealing effect of the added
chemotherapy cannot be ruled out. Additionally, in
multivariate analysis, ECE was associated with signifi-
cantly impaired locoregional (HR 2.939, p = 0.024), dis-
tant (HR 3.109, p = 0.007) and overall (HR 3.113, p =
0.001) control as well as impaired disease-specific (HR
2.160, p = 0.044) and disease-free (HR 1.876, p = 0.010)
survival rates. This study is well in line with the litera-
ture with ECE being a major risk factor for poor out-
come [31, 32]. Interestingly, in multivariate analysis,
positive nodal disease (HR 1.984, p = 0.025) was a pre-
dictor for impaired overall survival without significant
additional risk by ECE (HR 1.393, p = 0.205). In multi-
variate analysis, LVI was significantly associated with an
increased risk for overall relapses (HR 1.996, p = 0.030).
For LVI, it has to be taken into account, that only 68 pa-
tients had LVI reported by the pathologist, but 193 pa-
tients had positive nodal disease, thus a sampling error
cannot be excluded. Yet, LVI but not nodal positive dis-
ease remained statistically significant in multivariate
analysis.
All-in-all, our data indicates that further therapeutic
improvements for patients with locally advanced
HNSCC are still needed. Interestingly, in our cohort
more distant than locoregional failures were observed
pointing towards the need of innovative systemic therap-
ies such as immunotherapy [33, 34]. On the other hand,
the results for HPVOPC were excellent, supporting the
efforts to de-escalate treatment regimens in selected pa-
tients with HPVOPC. Apart from the HPV-status,
pathological features such as R-Status, LVI, PNI, positive
nodal disease and ECE provide solid information for the
assessment of the risk of recurrence. However, innova-
tive biomarkers [35–40] might further assist to select ap-
propriate patients for possible treatment modification,
such as dose-escalation or de-escalation, intensification
or de-intensification of chemotherapy or the addition of
immunotherapy [41].
Conclusion
In conclusion, the adjuvant LMU-KKG-cohort repre-
sents the “everyday patient” treated in our facility,
affirming previously described risk factors and compares
in line with historical cohorts, thus laying a sound foun-
dation for further translational research within the
framework of a clinical cooperation group.
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